Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

Key facts

Copied from the official Grants.gov record. Last verified October 29, 2026.

Program name

Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

Issuing agency

National Institutes of Health (Department of Health and Human Services)

Opportunity number

FOR-TR-27-002

Funding type

Cooperative Agreement

Funding purpose

Health

Status

Forecasted

Application deadline

Forecasted · estimated close February 17, 2026 (agency estimate)

Agency estimates

Estimated posting: October 15, 2025. Estimated award date: December 17, 2026. Estimates can change.

Published award range

Not published by the agency

Cost sharing or match required

No

Eligible applicants (official categories)

• State governments
• County governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities/Indian housing authorities
• Native American tribal organizations (other than Federally recognized tribal governments)
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Private institutions of higher education
• For profit organizations other than small businesses
• Small businesses

Relevant to

Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.

Geographic restrictions

None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.

Assistance Listing (CFDA)

93.350

Official source

View on Grants.gov ↗

Application URL

www.grants.gov/search-results-detail/359866 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.

Source identifier

Grants.gov opportunity ID 359866 · Funding opportunity number FOR-TR-27-002

Posted

June 27, 2025 · Source last updated June 27, 2025

Last verified

October 29, 2026 (against Grants.gov)

Data completeness

83% of key fields published by the sourceNot published: published funding range, eligibility criteria text.

Record confidence

mediumforecast — dates and amounts are agency estimates.

Description (from the official listing)

The National Center for Advancing Translational Science (NCATS) seeks to advance its mission by advancing research on extracellular vesicles (EVs) and their use as therapeutics in the field of regenerative medicine.The main objective of this program, Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe), is to support the translation of EV-based therapeutics in regenerative medicine. EVs, like exosomes and microvesicles, are crucial mediators of intercellular communication, carrying diverse cargo like proteins, nucleic acids, and lipids. In regenerative medicine, EVs play a significant role by influencing cellular behaviors during tissue repair and regeneration. Due to their natural function in intercellular communication, EVs represent a novel, cell-free, therapeutic tool. EVs can be further engineered to deliver therapeutic agents or modulate signaling pathways involved in repair/regeneration.Areas of interest for ExTReMe could include, but are not limited to:direct EV therapy (stem cell-isolated EVs produced under GLP conditions, and stored as off-the-shelf therapies);designer EVs (personalized to the individual patient’s needs).Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network

Agency contact

Christine Happel, Ph.D. National Center for Advancing Translational Sciences (NCATS)
christine.happel@nih.gov